Upadacitinib治疗特应性皮炎的长期安全性和有效性综述。

Q1 Medicine

Skin therapy letter Pub Date : 2025-09-01

Mohamad R Taha, Stephen K Tyring

{"title":"Upadacitinib治疗特应性皮炎的长期安全性和有效性综述。","authors":"Mohamad R Taha, Stephen K Tyring","doi":"","DOIUrl":null,"url":null,"abstract":"Atopic dermatitis (AD) is a common inflammatory skin condition characterized by erythema and intense pruritus. A key pathway implicated in its pathogenesis is the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathway. Upadacitinib, a JAK inhibitor, has been approved for the treatment of moderate-to-severe AD. This review evaluates the long-term safety and efficacy of upadacitinib in AD, incorporating findings from the Measure Up 1 and Measure Up 2 phase 3 studies.","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"30 5","pages":"5-7"},"PeriodicalIF":0.0000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Review of the Long-Term Safety and Efficacy of Upadacitinib in the Treatment of Atopic Dermatitis.\",\"authors\":\"Mohamad R Taha, Stephen K Tyring\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Atopic dermatitis (AD) is a common inflammatory skin condition characterized by erythema and intense pruritus. A key pathway implicated in its pathogenesis is the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathway. Upadacitinib, a JAK inhibitor, has been approved for the treatment of moderate-to-severe AD. This review evaluates the long-term safety and efficacy of upadacitinib in AD, incorporating findings from the Measure Up 1 and Measure Up 2 phase 3 studies.\",\"PeriodicalId\":21829,\"journal\":{\"name\":\"Skin therapy letter\",\"volume\":\"30 5\",\"pages\":\"5-7\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Skin therapy letter\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Skin therapy letter","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

特应性皮炎（AD）是一种常见的炎症性皮肤疾病，其特征是红斑和强烈的瘙痒。Janus kinase (JAK)/signal transducer and activator of transcription （STAT）信号通路是其发病机制的一个关键通路。Upadacitinib是一种JAK抑制剂，已被批准用于治疗中重度AD。本综述评估了upadacitinib治疗AD的长期安全性和有效性，纳入了Measure Up 1和Measure Up 2 3期研究的结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

本刊更多论文

A Review of the Long-Term Safety and Efficacy of Upadacitinib in the Treatment of Atopic Dermatitis.

Atopic dermatitis (AD) is a common inflammatory skin condition characterized by erythema and intense pruritus. A key pathway implicated in its pathogenesis is the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathway. Upadacitinib, a JAK inhibitor, has been approved for the treatment of moderate-to-severe AD. This review evaluates the long-term safety and efficacy of upadacitinib in AD, incorporating findings from the Measure Up 1 and Measure Up 2 phase 3 studies.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Skin therapy letter Medicine-Medicine (all)

CiteScore

2.80

自引率

0.00%

发文量

期刊介绍： The premier international journal on the latest advances, techniques and practice in conservation and restoration from around the world.